Healio

Ellipsoid zone faces challenges as trial endpoint

Please provide your email address to receive an email when new articles are posted on . “It is exciting that the FDA at least has indicated that the status of the photoreceptors, their preservation ...
Healio

Ellipsoid zone biomarker may help predict geographic atrophy progression

Please provide your email address to receive an email when new articles are posted on . Ellipsoid zone integrity may be an important biomarker in predicting the progression of geographic atrophy in ...
Ophthalmology Times

Phase 2 topline data: Ocugen OCU410 reduces geographic atrophy lesion growth by 31% at 12 months

Medium-dose OCU410 met the 12-month primary endpoint, reducing GA lesion growth by 31% versus control (P < .05), with ...

Ocugen Eye Disease Gene Therapy Data Trails Earlier Results, Stocks Falls

Ocugen Inc. OCGN shares are down during Tuesday’s session following topline data from its Phase 2 ArMaDa trial of OCU410.